机构:[1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[3]Department of Pathology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.[4]Department of Pathology, Sichuan Provincial People's Hospital, Chengdu, China.四川省人民医院[5]Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
This work was supported by the 1·3·5 project for disciplines of excellence
(ZYGD18012); the Technological Innovation Project of Chengdu New Industrial
Technology Research Institute (2017-CY02–00026-GX).
第一作者机构:[1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.[2]Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, China.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.[2]Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, China.
推荐引用方式(GB/T 7714):
Li Fengling,Yang Yongquan,Wei Yani,et al.Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer[J].NPJ BREAST CANCER.2022,8(1):doi:10.1038/s41523-022-00491-1.
APA:
Li Fengling,Yang Yongquan,Wei Yani,Zhao Yuanyuan,Fu Jing...&Bu Hong.(2022).Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer.NPJ BREAST CANCER,8,(1)
MLA:
Li Fengling,et al."Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer".NPJ BREAST CANCER 8..1(2022)